04X.F PERSONALIS INC. DL-001

Healthcare Oil, Gas & Consumable Fuels Frankfurt Exchange
14.25 EUR
Close of Nov 11, 2026
4.23 16.00
Market cap
EUR 1.54B
P/E
-
P/B
8.02x
ROE
-59.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 04X.F undervalued?

Graham number

The Graham number of PERSONALIS INC. DL-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PERSONALIS INC. DL-001 fundamental analysis

No fundamental analysis for PERSONALIS INC. DL-001 yet.

PERSONALIS INC. DL-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PERSONALIS INC. DL-001

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional…

Full company profile